

# Are You Diagnosed With Hepatocellular Carcinoma?



Researchers at the National Institutes of Health (NIH) in Bethesda, Maryland are investigating if nivolumab given in combination with tadalafil and vancomycin may help liver tumors to shrink. Nivolumab is an immune treatment agent that helps the immune system effectively fight cancer. Tadalafil is considered to be a treatment sensitizer for cancer and vancomycin is an antibiotic that alters the gut bacteria leading to a liver specific immune response by the patient. Current treatment options for patients with liver cancers, including hepatocellular carcinoma (HCC) and advanced liver cancers are limited. This Research study may provide answers for researchers for a new treatment that can help patients with hepatocellular carcinoma or metastases to the liver from colorectal or pancreatic cancer for which standard treatment has not worked.

## DESIGN OF THE STUDY:

- Physical exam and blood testing
- Scan of the chest, abdomen, and pelvis
- Participants will receive the study drugs in 4-week cycles
- There is no cost for study related medication, tests or procedures

## TO BE ELIGIBLE:

- Must be 18 years or older
- Diagnosed with Hepatocellular Carcinoma
- No signs of liver failure

The NIH Clinical Center, America's Research Hospital located in Bethesda, MD  
Metro red line (Medical Center stop)

**NIH Clinical Center Office of Patient Recruitment**  
800-411-1222 (TTY users call 800-877-8339 TTY / ASCII)  
Se habla español  
Email: [PRPL@cc.nih.gov](mailto:PRPL@cc.nih.gov)  
Online: <https://go.usa.gov/xpZx6>  
Refer to study #19-C-0033



**NATIONAL  
CANCER  
INSTITUTE**